| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | TNFRSF8; Ki-1; D1S166E |
| Entrez GeneID | 943 |
| clone | 4D1C2 |
| WB Predicted band size | 63.7kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD30 (AA: extra 19-379) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇关于CD30抗体的代表性文献概览：
---
1. **文献名称**：*Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas*
**作者**：Younes A, et al.
**摘要**：该研究报道了抗体药物偶联物Brentuximab vedotin在复发/难治性CD30阳性霍奇金淋巴瘤和间变性大细胞淋巴瘤患者中的II期临床试验结果，显示显著客观缓解率(ORR 75%)，奠定其作为靶向CD30疗法的里程碑。
---
2. **文献名称**：*Molecular cloning and expression of a new member of the nerve growth factor receptor family*
**作者**：Dürkop H, et al.
**摘要**：首次克隆并鉴定了CD30分子，揭示其属于肿瘤坏死因子受体超家族(TNFRSF8)，并阐述其在活化的T/B细胞及淋巴瘤细胞中的特异性表达，为后续靶向治疗奠定理论基础。
---
3. **文献名称**：*Antigenic modulation limits the efficacy of anti-CD30 antibody therapy*
**作者**：Rothe A, et al.
**摘要**：探讨CD30抗体治疗中因抗原-抗体复合物内化导致的靶点下调现象，提出联合组蛋白去乙酰化酶抑制剂(如Panobinostat)可逆转耐药性，为优化治疗方案提供机制支持。
---
(如需更多文献或细节，可进一步补充。)
CD30. a transmembrane glycoprotein in the tumor necrosis factor receptor (TNFR) superfamily, is primarily expressed on activated lymphocytes and a hallmark of certain lymphomas. Initially identified in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL), CD30 plays roles in cell signaling, survival, and immune regulation, though its exact biological functions remain partially understood. Its restricted expression in healthy tissues—mainly limited to a subset of activated T/B cells—makes it a promising therapeutic target for CD30-positive malignancies.
The development of CD30-targeted therapies, notably brentuximab vedotin, revolutionized treatment for relapsed/refractory HL and systemic ALCL. This antibody-drug conjugate (ADC) combines an anti-CD30 monoclonal antibody with a cytotoxic agent, enabling targeted delivery to CD30-expressing cells. Other approaches include bispecific antibodies and CD30-directed CAR-T cells, currently under investigation in clinical trials. Beyond oncology, CD30 is implicated in inflammatory diseases, spurring research into its role in autoimmune conditions.
Diagnostically, CD30 serves as a biomarker for identifying HL and ALCL in pathology, aiding differential diagnosis and treatment monitoring. Despite therapeutic success, resistance mechanisms and variable CD30 expression in tumors pose challenges, driving efforts to optimize targeting strategies. Ongoing research aims to expand CD30-based therapies into broader lymphoma subtypes and combinatorial regimens with immunotherapies, underscoring its enduring relevance in precision medicine.
×
